Videos

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

Christine Cooper, RN, BSN, explains anemia in myelofibrosis is managed by stimulating red blood cell production with medications, transfusions, and newer therapies that may stabilize red cell counts.

Key patient goals for managing myelofibrosis include improving quality of life by addressing low blood counts and constitutional symptoms, considering disease-modifying therapies and transplant to maximize longevity based on predicted survival, and incorporating personalized priorities through shared decision-making with their doctor when choosing treatments.

Patients should be directed to resources like the NCCN guidelines and ClinicalTrials.gov and provided with thorough discussions covering frequency of visits, required testing, medication administration, side effects to enable fully informed decisions.

To determine risk level in myelofibrosis, prognostic models are used which assign points to various clinical and pathological factors to calculate a risk score that categorizes patients as low, intermediate, or high risk; additional information like mutations and chromosomes can further refine risk stratification.

Patients with myelofibrosis commonly present with fatigue, weight loss, night sweats, bone pain, low blood counts, and concentration issues, with diagnosis requiring bone marrow biopsy.

Nurses treating patients with MPNs should remember to advocate for and empower them.

An oncology nurse said he wants patients to tell them about all their symptoms, so that they can get to the root of what is important and plan treatment accordingly.

Rebecca Testi, MSN, APN, APN-G, from Hackensack Meridian Health, explains ways to help support patients with myeloproliferative neoplasms.

Patrick Buxton, RN, BSN, discusses how chronic fatigue can significantly affect the quality of life in patients with myeloproliferative neoplasms.

Cheryl VerStrate, DNP, AGPCNP-BC, OCN, discusses why nurses should be prepared to discuss direct-to-consumer genomic testing with their patients.

Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.

Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MonumenTAL-1 study assessing talquetamab in multiple myeloma.

Oncology nurses should have open communication with patients and closely monitor their hemoglobin levels when dealing with patients with myelofibrosis who have or may have anemia.

Jennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.

According to Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN, patients with newly diagnosed myeloproliferative neoplasms may be unaware of the questions they should be asking their providers.

Lindsey Lyle, PA-C, MS, discusses how oncology nurses can work with their patients to determine if symptoms are related to their myeloproliferative neoplasm or another health condition.

Meredith Cummings BSN, RN, OCN, highlights her research on machine learning and its potential application in optimizing symptom management.

Alyssa Ridad BSN-RN, OCN; and Amanda McKaig, BSN, RN, OCN, discuss oncology nurse perceptions of medical cannabis.

Yelena Shames, MSA, ACNP-BC, CNRN, discusses when immune checkpoint inhibitor treatment should be paused because of laboratory abnormalities.

Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.

Elizabeth R. Cullen, MSN, ARNP, provides an overview of avasopasem manganese and its potential role in reducing severe oral mucositis for patients undergoing radiotherapy.

Tia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.

Seth Eisenberg, ASN, RN, OCN, BMTCN, discusses his research comparing plastic-backed pads and the Splashblocker.

Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.

Kellie Zeichner BSN, RN, OCN, explains how her institution created a standardized monitoring procedure for insulinoma care.

Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.

Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss the benefits of oral cryotherapy for patients receiving dose-dense doxorubicin.

Melanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.